HRP20171053T1 - Derivati oksokinazolinil-butanamida - Google Patents
Derivati oksokinazolinil-butanamida Download PDFInfo
- Publication number
- HRP20171053T1 HRP20171053T1 HRP20171053TT HRP20171053T HRP20171053T1 HR P20171053 T1 HRP20171053 T1 HR P20171053T1 HR P20171053T T HRP20171053T T HR P20171053TT HR P20171053 T HRP20171053 T HR P20171053T HR P20171053 T1 HRP20171053 T1 HR P20171053T1
- Authority
- HR
- Croatia
- Prior art keywords
- denotes
- atoms
- pharmaceutically acceptable
- stereoisomers
- proportions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- 125000003226 pyrazolyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- -1 methoxyethyl Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (11)
1. Spojevi s formulom I
[image]
naznačeni time da
Z označava
[image]
ili
[image]
X označava CH ili N,
R1, R2 svaki, međusobno neovisno, označavaju H, F ili Cl,
R3 označava H, F, Cl, CH3 ili OCH3,
R4 označava H, F, A, CN, OA ili Y,
R5 označava H, F, A ili OA,
R6 označava CN ili 2-pirimidinil,
R7 označava Het2,
A označava nerazgranati ili razgranati alkil s 1 - 8 C atoma, pri čemu jedna ili dvije ne susjedne CH- i/ili CH2-skupine mogu biti zamijenjene s N- ili O-atomima i pri čemu 1-7 H-atoma mogu biti zamijenjeni s F, Cl i/ili OH,
Y označava pirazolil, koji može biti supstituiran s A ili (CH2)nHet1,
Het1 označava pirolidinil, piperidinil, morfolinil ili piperazinil, svaki od kojih može biti supstituiran s A,
Het2 označava pirazolil, imidazolil, oksazolil, izoksazolil, pirolil, tiazolil, furanil ili tienil, svaki od kojih može biti supstituiran s A,
n je 0, 1, 2, 3 ili 4,
i njihove farmaceutski prihvatljive soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
2. Spojevi prema zahtjevu 1 naznačeni time da
A označava nerazgranati ili razgranati alkil s 1 - 6 C-atoma, pri čemu jedna ili dvije ne susjedne CH2-skupine mogu biti zamijenjene s O-atomima i pri čemu 1-7 H-atoma mogu biti zamijenjeni s F i/ili OH,
i njihovi farmaceutski prihvatljivi solvati, soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
3. Spojevi prema zahtjevu 1, naznačeni time da
R1, R2 svaki, međusobno neovisno, označavaju H, F ili Cl,
R3 označava H, F, Cl, CH3 ili OCH3,
R4 označava H, F, A, CN, OA ili Y,
R5 označava H, F, A ili OA,
A označava nerazgranati ili razgranati alkil s 1 - 6 C-atoma, pri čemu 1-3 H-atoma mogu biti zamijenjeni s F i/ili OH,
Y označava pirazolil, koji može biti supstituiran s A, metoksietilom, ili (CH2)nHet1,
Het1 označava pirolidinil, piperidinil, morfolinil ili piperazinil, svaki od kojih može biti supstituiran s A,
Het2 označava pirazolil, imidazolil, oksazolil, izoksazolil, pirolil, tiazolil, furanil ili tienil, svaki od kojih može biti supstituiran s A,
A označava nerazgranati ili razgranati alkil s 1 - 6 C-atoma, pri čemu 1-3 H-atoma mogu biti zamijenjeni s F i/ili OH,
n je 0, 1, 2, 3 ili 4,
i njihove farmaceutski prihvatljive soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
4. Spojevi prema zahtjevu 1, naznačeni time da
R1 označava H,
R2 označava H ili F,
R3 označava H, CH3 ili F,
R4 označava H, CN, OCH3, 1-etil-1 H-pirazol-4-il, 1-(2-metoksi-etil)-1 H-pirazol-4-il ili 1-(2-pirolidin-1-il-etil)-1H-pirazol-4-il,
R5 označava H, CH3, F ili OCH3,
Het2 označava pirazolil ili imidazolil, svaki od kojih može biti supstituiran s A,
A označava nerazgranati ili razgranati alkil s 1 - 6 C-atoma, pri čemu 1-3 H-atoma mogu biti zamijenjeni s F i/ili OH,
i njihove farmaceutski prihvatljive soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
5. Spojevi prema zahtjevu 1, naznačeni time da se odabrani iz skupine koju čine
[image]
i njihovi farmaceutski prihvatljivi solvati, soli, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima.
6. Postupak za pripremanje spojeva s formulom I prema zahtjevima 1-5 i njihovih farmaceutski prihvatljivih soli, solvata, tautomera i stereoizomera, naznačen time da spoj s formulom II
[image]
u kojoj Z ima značenja navedena u zahtjevu 1,
reagira
sa spojem s formulom III
[image]
u kojoj R1, R2 i R3 imaju značenja navedena u zahtjevu 1,
i L označava Cl, Br, I ili slobodnu ili reaktivno funkcionalno modificiranu OH skupinu,
i/ili
baza ili kiselina s formulom I se pretvara u jednu od njihovih soli.
7. Lijekovi naznačeni time da sadrže barem jedan spoj s formulom I prema zahtjevu 1 i/ili njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, te proizvoljno farmaceutski prihvatljiv nosač, pomoćno sredstvo ili prijenosnik.
8. Spojevi s formulom I prema zahtjevu 1 i njihove farmaceutski prihvatljive soli, solvati, tautomeri i stereoizomeri, uključujući njihove smjese u svim omjerima, naznačeni time da su za uporabu za liječenje i/ili prevenciju raka, multiple skleroze, kardiovaskularnih bolesti, ozljede središnjeg živčanog sustava i različitih oblika upala.
9. Spojevi za uporabu prema zahtjevu 8 naznačeni time da su za liječenje i/ili prevenciju bolesti koje se biraju iz skupine koju čine karcinom glave, vrata, oka, usta, grla, jednjaka, bronha, grkljana, ždrijela, prsnog koša, kostiju, pluća, debelog crijeva, rektuma, želuca, prostate, mokraćnog mjehura, maternice, grlića maternice, dojke, jajnika, testisa ili drugih reproduktivnih organa, kože, štitnjače, krvi, limfnih čvorova, bubrega, jetre, gušterače, mozga, središnjeg živčanog sustava, solidnih tumora i hematopoetskih tumora.
10. Lijekovi naznačeni time da sadrže barem jedan spoj s formulom I prema zahtjevu 1 i/ili njihove farmaceutski prihvatljive soli, solvate, i stereoizomere, uključujući njihove smjese u svim omjerima, te barem jedan dodatni aktivni sastojak lijeka.
11. Komplet (kit) naznačen time da sadrži odvojena pakiranja
(a) učinkovite količine spoja s formulom I prema zahtjevu 1 i/ili njihovih farmaceutski prihvatljivih soli, solvata, soli i stereoizomera uključujući njihove smjese u svim omjerima, (b) učinkovite količine dodatnog aktivnog sastojka lijeka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003815 | 2013-07-31 | ||
| EP14739045.4A EP3027598B1 (en) | 2013-07-31 | 2014-07-10 | Oxoquinazolinyl-butanamide derivatives |
| PCT/EP2014/001895 WO2015014442A1 (en) | 2013-07-31 | 2014-07-10 | Oxoquinazolinyl-butanamide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171053T1 true HRP20171053T1 (hr) | 2017-10-06 |
Family
ID=48915813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171053TT HRP20171053T1 (hr) | 2013-07-31 | 2017-07-10 | Derivati oksokinazolinil-butanamida |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9901577B2 (hr) |
| EP (1) | EP3027598B1 (hr) |
| JP (1) | JP6423875B2 (hr) |
| KR (1) | KR102331389B1 (hr) |
| CN (1) | CN105392784B (hr) |
| AR (1) | AR097087A1 (hr) |
| AU (1) | AU2014298955B2 (hr) |
| BR (1) | BR112016001645B1 (hr) |
| CA (1) | CA2919905C (hr) |
| DK (1) | DK3027598T3 (hr) |
| ES (1) | ES2632988T3 (hr) |
| HK (1) | HK1222391A1 (hr) |
| HR (1) | HRP20171053T1 (hr) |
| HU (1) | HUE032846T2 (hr) |
| IL (1) | IL243734B (hr) |
| LT (1) | LT3027598T (hr) |
| MX (1) | MX359656B (hr) |
| NZ (1) | NZ716593A (hr) |
| PL (1) | PL3027598T3 (hr) |
| PT (1) | PT3027598T (hr) |
| RS (1) | RS56211B1 (hr) |
| RU (1) | RU2669393C2 (hr) |
| SG (1) | SG11201600743WA (hr) |
| SI (1) | SI3027598T1 (hr) |
| WO (1) | WO2015014442A1 (hr) |
| ZA (1) | ZA201601333B (hr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016025396A2 (pt) * | 2014-05-07 | 2017-08-15 | Merck Patent Gmbh | derivados de heterociclil-butanamida |
| EP3371166B1 (en) * | 2015-11-02 | 2019-11-20 | Merck Patent GmbH | 1,4-dicarbonyl-piperidyl derivatives |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201615282D0 (en) * | 2016-09-08 | 2016-10-26 | Univ Bath | Tankyrase inhibitors |
| KR102606799B1 (ko) | 2016-12-30 | 2023-11-28 | 미토브리지, 인크. | 폴리-adp 리보스 폴리머라제 (parp) 억제제 |
| KR20200103760A (ko) * | 2017-12-21 | 2020-09-02 | 리본 테라퓨틱스 인코포레이티드 | Parp14 억제제로서의 퀴나졸리논 |
| CN109180702B (zh) * | 2018-10-29 | 2021-11-30 | 四川大学 | 一种噻吩并嘧啶酮化合物及其用途 |
| CN113166097A (zh) | 2018-12-03 | 2021-07-23 | 默克专利股份公司 | 作为端锚聚合酶抑制剂的4-杂芳基羰基-n-(苯基或杂芳基)哌啶-1-甲酰胺 |
| WO2023161881A1 (en) * | 2022-02-25 | 2023-08-31 | Glaxosmithkline Intellectual Property Development Limited | Cytotoxicity targeting chimeras for ccr2-expressing cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9202915D0 (en) * | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
| EA005890B1 (ru) * | 2000-05-26 | 2005-06-30 | Айденикс (Кайман) Лимитед | СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US20040176361A1 (en) * | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| EA009469B1 (ru) * | 2003-03-12 | 2007-12-28 | Кудос Фармасеутикалс Лимитед | Производные фталазинона |
| EP1771422B1 (en) * | 2004-06-30 | 2011-02-16 | Janssen Pharmaceutica NV | Quinazolinone derivatives as parp inhibitors |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| CN101492425A (zh) * | 2009-02-27 | 2009-07-29 | 无锡市凯奥善生物医药科技有限公司 | 一类parp抑制剂的化合物 |
| US9181266B2 (en) | 2011-07-13 | 2015-11-10 | Novartis Ag | 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| EP2890696A1 (en) * | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
-
2014
- 2014-07-10 EP EP14739045.4A patent/EP3027598B1/en active Active
- 2014-07-10 AU AU2014298955A patent/AU2014298955B2/en not_active Ceased
- 2014-07-10 SI SI201430283T patent/SI3027598T1/sl unknown
- 2014-07-10 RS RS20170679A patent/RS56211B1/sr unknown
- 2014-07-10 PT PT147390454T patent/PT3027598T/pt unknown
- 2014-07-10 PL PL14739045T patent/PL3027598T3/pl unknown
- 2014-07-10 CA CA2919905A patent/CA2919905C/en active Active
- 2014-07-10 CN CN201480042153.0A patent/CN105392784B/zh active Active
- 2014-07-10 HU HUE14739045A patent/HUE032846T2/en unknown
- 2014-07-10 RU RU2016106952A patent/RU2669393C2/ru active
- 2014-07-10 JP JP2016530371A patent/JP6423875B2/ja active Active
- 2014-07-10 WO PCT/EP2014/001895 patent/WO2015014442A1/en active Application Filing
- 2014-07-10 DK DK14739045.4T patent/DK3027598T3/da active
- 2014-07-10 SG SG11201600743WA patent/SG11201600743WA/en unknown
- 2014-07-10 US US14/909,365 patent/US9901577B2/en active Active
- 2014-07-10 NZ NZ716593A patent/NZ716593A/en not_active IP Right Cessation
- 2014-07-10 ES ES14739045.4T patent/ES2632988T3/es active Active
- 2014-07-10 BR BR112016001645-9A patent/BR112016001645B1/pt not_active IP Right Cessation
- 2014-07-10 MX MX2016001136A patent/MX359656B/es active IP Right Grant
- 2014-07-10 KR KR1020167005040A patent/KR102331389B1/ko active IP Right Grant
- 2014-07-10 LT LTEP14739045.4T patent/LT3027598T/lt unknown
- 2014-07-28 AR ARP140102799A patent/AR097087A1/es active IP Right Grant
-
2016
- 2016-01-21 IL IL243734A patent/IL243734B/en active IP Right Grant
- 2016-02-26 ZA ZA2016/01333A patent/ZA201601333B/en unknown
- 2016-09-06 HK HK16110560.1A patent/HK1222391A1/zh not_active IP Right Cessation
-
2017
- 2017-07-10 HR HRP20171053TT patent/HRP20171053T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171053T1 (hr) | Derivati oksokinazolinil-butanamida | |
| JP2015529229A5 (hr) | ||
| HRP20200180T1 (hr) | Derivati (aza-)izokinolinona | |
| HRP20171783T1 (hr) | Derivati imidazopirazinona | |
| RU2015115278A (ru) | Производные гидропирролопиррола для применения в качестве ингибиторов синтазы жирных кислот | |
| JP2015524450A5 (hr) | ||
| JP2015515961A5 (hr) | ||
| JP2015511609A5 (hr) | ||
| HRP20200681T1 (hr) | Ciklički eter pirazol-4-il-heterociklil-karboksamidni spojevi i postupci njihove upotrebe | |
| CN105008343B (zh) | 作为选择性***受体降解剂的苯并噻吩衍生物及其组合物 | |
| RU2016147727A (ru) | Гетероциклилбутанамидные производные | |
| JP2020097596A5 (hr) | ||
| HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
| HRP20202065T1 (hr) | Kristalni oblik inhibitora mdm2 | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| JP2018510191A5 (hr) | ||
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| NZ630205A (en) | Enhancer of zeste homolog 2 inhibitors | |
| JP2016513661A5 (hr) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| SI3030554T1 (en) | PIPERIDIN-SEA DERIVATIVES | |
| HRP20141034T1 (hr) | Spojevi koji sadrže (s)-2-amino-1-(4-klorofenil)-1-[4-(1h-pirazol-4-il)-fenil]-etanol kao modulator proteinskih kinaza | |
| HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
| JP2016507502A5 (hr) | ||
| HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk |